Daniela Pugliese

Faculty Profile Webpagehttps://docenti.unicatt.it/ppd2/linkPpdDocente?cod_docente=54991

Research activity per year

Academic discipline

MEDS-05/A - Internal Medicine

Fingerprint

Dive into the research topics where Daniela Pugliese is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus
Fiorino, G., Caprioli, F. A., Onali, S., Macaluso, F. S., Bezzio, C., Armelao, F., Armuzzi, A., Baldoni, M., Bodini, G., Castiglione, F., Daperno, M., Festa, S., Furfaro, F., Gionchetti, P., Leone, S., Luglio, G., Milla, M., Mocci, G., Napolitano, D. & Orlando, A. & 17 others, Previtali, E., Pugliese, D., Renna, S., Rispo, A., Saibeni, S., Sampietro, G., Savarino, E., Scaldaferri, F., Spagnuolo, R., Variola, A., Viola, A., Viscido, A., Vitale, G., Zaetta, D., Zingone, F., Colli, A. & Fantini, M. C., 2025, In: Digestive and Liver Disease. N/A, p. N/A-N/A
Research output: Contribution to journal › Article
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
Lopetuso, L. R., Deleu, S., Puca, P., Abreu, M. T., Armuzzi, A., Barbara, G., Caprioli, F., Chieng, S., Costello, S. P., Damiani, A., Danese, S., Del Chierico, F., D'Haens, G., Dotan, I., Facciotti, F., Falony, G., Fantini, M. C., Fiorino, G., Gionchetti, P. & Godny, L. & 28 others, Hart, A., Kupčinskas, J., Iqbal, T., Laterza, L., Lombardini, L., Maharshak, N., Marasco, G., Masucci, L., Papa, A., Paramsothy, S., Petito, V., Piovani, D., Pugliese, D., Putignani, L., Raes, J., Ribaldone, D. G., Sanguinetti, M., Savarino, E. V., Sokol, H., Vetrano, S., Ianiro, G., Cammarota, G., Cominelli, F., Pizarro, T. T., Tilg, H., Gasbarrini, A., Vermeire, S. & Scaldaferri, F., 2025, In: Inflammatory Bowel Diseases. 31, 9, p. 2408-2419 12 p.
Research output: Contribution to journal › Article
Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study
Privitera, G., Monastero, L., Melita, E., Schiavoni, E., Napolitano, D., Barini, A., Barini, A., Tolusso, B., Laterza, L., Gasbarrini, A., Scaldaferri, F., Pugliese, D. & Armuzzi, A., 2025, In: Digestive and Liver Disease. N/A, p. N/A-N/A
Research output: Contribution to journal › Article
Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases
Calvez, V., Puca, P., Di Vincenzo, F., Del Gaudio, A., Bartocci, B., Murgiano, M., Iaccarino, J., Parand, E., Napolitano, D., Pugliese, D., Gasbarrini, A. & Scaldaferri, F., 2025, In: Biomedicines. 13, 2, p. N/A-N/A
Research output: Contribution to journal › Article
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium
Lenti, M. V., Ribaldone, D. G., Borrelli, D. A. F., Vernero, M., Barberio, B., De, R. M., Savarino, E. V., Kav, T., Blesl, A., Franzoi, M., Grochenig, H. P., Pugliese, D., Ianiro, G., Porcari, S., Cammarota, G., Gasbarrini, A., Spagnuolo, R., Ellul, P., Foteinogiannopoulou, K. & Koutroubakis, I. & 49 others, Argyriou, K., Cappello, M., Jauregui-Amezaga, A., Demarzo, M. G., Silvestris, N., Armuzzi, A., Sottotetti, F., Bertani, L., Festa, S., Eder, P., Pedrazzoli, P., Lasagna, A., Vanoli, A., Gambini, G., Santacroce, G., Rossi, C. M., Delliponti, M., Klersy, C., Corazza, G. R., Di, S. A., Mengoli, C., Aronico, N., Lepore, F., Broglio, G., Merli, S., Natalello, G., Alimenti, E., Scalvini, D., Muscarella, S., Agustoni, F., Pagani, A., Chiellino, S., Corallo, S., Musella, V., Cannizzaro, R., Vecchi, M., Caprioli, F., Gabbiadini, R., Dal, B. A., Premoli, A., Locati, L. D., Buda, A., Contaldo, A., Schiepatti, A., Biagi, F., Morano, D., Cuce, M., Kotsakis, A. & De, L. G., 2024, In: ESMO Open. 9, 7, p. N/A-N/A
Research output: Contribution to journal › Article

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
Guidi, L. (Creator), Pugliese, D. (Creator), Tonucci, T. P. (Creator), Bertani, L. (Creator), Costa, F. (Creator), Privitera, G. (Creator), Tolusso, B. (Creator), Di Mario, C. (Contributor), Albano, E. (Creator), Tapete, G. (Creator), Gremese, E. (Creator), Papa, A. (Creator), Gasbarrini, A. (Creator), Rapaccini, G. L. (Creator) & Armuzzi, A. (Creator), SAGE Journals, 2019
DOI: 10.25384/sage.c.4653497, https://sage.figshare.com/collections/Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/4653497
Dataset
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
Guidi, L. (Creator), Pugliese, D. (Creator), Tonucci, T. P. (Creator), Bertani, L. (Creator), Costa, F. (Creator), Privitera, G. (Creator), Tolusso, B. (Creator), Di Mario, C. (Contributor), Albano, E. (Creator), Tapete, G. (Creator), Gremese, E. (Creator), Papa, A. (Creator), Gasbarrini, A. (Creator), Rapaccini, G. L. (Creator) & Armuzzi, A. (Creator), SAGE Journals, 2019
DOI: 10.25384/sage.c.4653497, https://sage.figshare.com/collections/Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/4653497
Dataset
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
Guidi, L. (Creator), Pugliese, D. (Creator), Tonucci, T. P. (Creator), Bertani, L. (Creator), Costa, F. (Creator), Privitera, G. (Creator), Tolusso, B. (Creator), Di Mario, C. (Contributor), Albano, E. (Creator), Tapete, G. (Creator), Gremese, E. (Creator), Papa, A. (Creator), Gasbarrini, A. (Creator), Rapaccini, G. L. (Creator) & Armuzzi, A. (Creator), SAGE Journals, 2019
DOI: 10.25384/sage.c.4653497.v1, https://sage.figshare.com/collections/Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/4653497/1
Dataset
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
Guidi, L. (Creator), Pugliese, D. (Creator), Tonucci, T. P. (Creator), Bertani, L. (Creator), Costa, F. (Creator), Privitera, G. (Creator), Tolusso, B. (Creator), Di Mario, C. (Contributor), Albano, E. (Creator), Tapete, G. (Creator), Gremese, E. (Creator), Papa, A. (Creator), Gasbarrini, A. (Creator), Rapaccini, G. L. (Creator) & Armuzzi, A. (Creator), SAGE Journals, 2019
DOI: 10.25384/sage.c.4653497.v1, https://sage.figshare.com/collections/Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/4653497/1
Dataset
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
Tursi, A. (Creator), Mocci, G. (Creator), Scaldaferri, F. (Creator), Napolitano, D. (Creator), Maresca, R. (Creator), Pugliese, D. (Creator), Semprucci, G. (Creator), Savarino, E. (Creator), Cuomo, A. (Creator), Donnarumma, L. (Creator), Bodini, G. (Creator), Pasta, A. (Creator), Maconi, G. (Creator), Cataletti, G. (Creator), Pranzo, G. (Creator), Rodinò, S. (Creator), Sebkova, L. (Creator), Costa, F. (Creator), Ferronato, A. (Creator), Gaiani, F. (Creator), Marzo, M. (Creator), Luppino, I. (Creator), Fabiano, G. (Creator), Paese, P. (Creator), Elisei, W. (Creator), Monterubbianesi, R. (Creator), Faggiani, R. (Creator), Grossi, L. (Creator), Serio, M. (Creator), Scarcelli, A. (Creator), Lorenzetti, R. (Creator), Allegretta, L. (Creator), Chiri, S. (Creator), Grasso, G. (Creator), Antonelli, E. (Creator), Bassotti, G. (Creator), Spagnuolo, R. (Creator), Luzza, F. (Creator), Fanigliulo, L. (Creator), Rocco, G. (Creator), Sacchi, C. (Creator), Zampaletta, C. (Creator), Rocchi, C. (Creator), Bolognini, L. (Creator), Bendia, E. (Creator), Bianco, M. A. (Creator), Capone, P. (Creator), Meucci, C. (Creator), Colucci, R. (Creator), Tonti, P. (Creator), Neve, V. (Creator), Della Valle, N. (Creator), Felice, C. (Creator), Pica, R. (Creator), Cocco, A. (Creator), Forti, G. (Creator), Onidi, F. M. (Creator), Usai Satta, P. (Contributor), Checchin, D. (Creator), Gravina, A. G. (Creator), Pellegrino, R. (Creator), Picchio, M. (Creator) & Papa, A. (Creator), Taylor & Francis, 2024
DOI: 10.6084/m9.figshare.25039971, https://tandf.figshare.com/articles/dataset/Ustekinumab_safety_and_effectiveness_in_patients_with_ulcerative_colitis_results_from_a_large_real-life_study/25039971
Dataset

Daniela Pugliese

Personal profile

Academic discipline

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus

Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference

Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study

Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases

A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study

Daniela Pugliese

Personal profile

Academic discipline

Fingerprint

Collaborations and top research areas from the last five years

Research output

Datasets